Skip to main content

The exceptional six-month data from Xeltis’ first-in-human (FIH) aXess conduit trial has been published in the Journal of Vascular Access.

View on Journal of Vascular Access
In six-month data from the FIH trial, the aXess vascular conduit demonstrated high patency rates (80% primary patency, 100% secondary patency). At six months, a 0% infection rate and low re-intervention rates were reported, resulting in a highly favorable safety profile. Hemodialysis was successfully performed through the graft, and compared to current standard of care measures, which typically show lower rates of patency combined with a greater risk of infection or rejection, aXess demonstrated extremely promising results.
The trial is ongoing, with outstanding 12-month data presented by Professor Dr. Frans Moll at the VEITHSymposium 2023.